GILD vs VRTX
GILD and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $181.46B | $137.96B |
| P/E (TTM) | 21.6 | 31.7 |
| P/B | 15.34 | 6.81 |
| P/S | 6.2x | 11.5x |
| Dividend yield | 2.21% | — |
| Revenue | $30.46B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 2.4% | 8.9% |
| Net income | -$3.24B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 1672.9% | 838.1% |
| EPS, diluted | $-2.65(TTM) | $17.17(TTM) |
| EBIT margin | 34.0% | 34.8% |
| ROE | 71.9% | 19.5% |
| ROIC | 26.7% | 25.0% |
| 1y total return | +32.4% | +39.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs VRTX
| Metric | GILD | VRTX |
|---|---|---|
| End value | $21.6K | $62.8K |
| Total return | +116.2% | +527.7% |
| CAGR | +7.7% | +19.4% |
| Volatility | 25.7% | 32.8% |
| Sharpe | 0.27 | 0.59 |
| Sortino | 0.39 | 0.87 |
| Max drawdown | -32.5% | -41.6% |
Based on 2600 common trading days, 2016-04-28 → 2026-08-31 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)